Hui Gan

The University of Melbourne — Australia

Medicine · Health Sciences

66h-index20.0kcitations700works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(196), Cancer Immunotherapy and Biomarkers(67), HER2/EGFR in Cancer Research(58), Monoclonal and Polyclonal Antibodies Research(57), Radiopharmaceutical Chemistry and Applications(41)

Publications653 total

Treatment outcomes and toxicity of carboplatin after relapse in patients with glioma
Neuro-Oncology Practice·2025
DDDR-19. An optimized explant organoid method for preclinical brain tumour research
Neuro-Oncology·2025Open Access
TIP-07. IPAX-2: Phase 1 safety and dose finding study of [131I]IPA plus standard of care in patients with newly diagnosed glioblastoma
Neuro-Oncology·2025
CTNI-25. MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): CENTRAL NUCLEAR MEDICINE AND RADIATION ONCOLOGY REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING
Neuro-Oncology·2025Open Access
EXTH-46. IL-15 armored glypican-3 chimeric antigen receptor T cells exhibit antitumor in vitro and in murine models of glioblastoma
Neuro-Oncology·2025Open Access
IMMU-35. CD3⁺CD4⁻CD8⁻ (Double-Negative) T-cells Provide Inflammatory Signals That Influence Myeloid Cells and Enhance Survival in Glioblastoma
Neuro-Oncology·2025Open Access
TIP-16. Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study
Neuro-Oncology·2025Open Access
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Neuro-Oncology·2025Open Access
Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma
Molecular Pharmaceutics·2025· 1 cited
Establishment of an in vivo analytical method for detecting total anti-UFH activity and pharmacokinetic study in PS and R15 in rats
PLoS ONE·2025Open Access
Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope
Cancers·2025· 1 citedOpen Access
[Advances in the mechanism and research of epithelial-derived alarmins in driving allergic diseases].
PubMed·2025
Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025· 1 citedOpen Access
Figure S7 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Supplementary Table 2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S8 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S4 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Supplementary Table 1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S6 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
Figure S1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
2025Open Access
page 1 of 33Next →

Frequent Co-authors

Andrew M. Scott(15), Andrew B. Lassman(6), Jill S. Barnholtz‐Sloan(5), Kenneth Aldape(5), Antony W. Burgess(5), Martin J. van den Bent(5), David A. Reardon(5), Floris P Barthel(4), Kevin C. Johnson(4), Frederick S. Varn(4), Emre Kocakavuk(4), Kevin Anderson(4), Samirkumar B. Amin(4), David M. Ashley(4), Daniel J. Brat(4), Mustafa Khasraw(4), Hoon Kim(4), D. Ryan Ormond(4), Erwin G. Van Meir(4), Colin Watts(4)